Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ovid Therapeutics Inc.

www.ovidrx.com

Latest From Ovid Therapeutics Inc.

BIO Stalwart Greenwood Announces Departure

Long-time CEO of the Biotechnology Innovation Organization will remain until after the 2020 election and help with the leadership transition.

Leadership Pricing Debate

Asia Deal Watch: Zogenix Partners Japanese Rights To Pediatric Epilepsy Therapy To Nippon Shinyaku

Nippon Shinyaku obtains rights to sell Dravet and Lennox-Gastaut syndrome drug Fintepla in its home market. Sun Pharma increases its ownership stake in Russia’s PJSC Biosintez.

Asia Pacific Commercial

Finance Watch: Anchiano, TCR2, Hoth And Stealth Make Seven US Biopharma IPOs For 2019

Public Company Edition: Four more IPOs in the US bring the year's total to seven – all in February. Also, Agenus launched its digital security offering, MacroGenics leads recent follow-on offerings and four companies reveal new job cuts.

Financing Business Strategies

Why The M&A Boom Many Expected In 2018 Didn’t Happen

High valuations, an uncertain biopharma macro environment and widespread use of US tax reform benefits for share buybacks and capital investments resulted in less major M&A than expected. Opinions vary widely on whether 2019 will be any different.

M & A Outlook 2019
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Ovid Therapeutics Inc.
  • Senior Management
  • Jeremy Levin, CEO
    Timothy Daly, Treasurer, SVP, Fin. & Corp. Controller
    Amit Rakhit, MD, Head, R&D & CMO
    Dirk Haasner, PhD, SVP, Global Reg. Affairs
  • Contact Info
  • Ovid Therapeutics Inc.
    Phone: (646) 661-7661
    1460 Broadway
    New York, NY 10036
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register